International Myeloma Workshop | Conference

MRD-Based Consolidation Dara-KRd Results in Quick Responses and High Rates of MRD Negativity in Newly Diagnosed Myeloma
September 13, 2021

Patients with newly diagnosed multiple myeloma experienced rapid responses and notable rates of minimal residual disease negativity following minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Talquetamab Yields Promising Phase 1 Data in Relapsed/Refractory Multiple Myeloma
September 12, 2021

Patients with relapsed/refractory multiple myeloma who were treated with the recommended phase 2 dose of talquetamab experienced positive clinical activity.

Long-Term Follow-Up Continues to Support Ide-Cel Use in Heavily Pretreated Relapsed/Refractory Myeloma
September 11, 2021

Continued efficacy of CAR T-cell therapy with idecabtagene vicleucel in patients with pretreated myeloma is evidenced by updated KarMMa trial findings presented at the 18th International Myeloma Workshop.